Cotización Oric Pharmaceuticals - ORIC

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

8.96

Postura de Compra

3.59

Postura de Venta

10.60

Volume Operado de la Acción

0.00 Rango del Día 0.00

6.33 Rango de 52 semanas 16.65

Capitalización de Mercado [m]

632.28M

Precio Anterior

8.96

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

420,837

Acciones en circulación

70,566,950

Rendimiento del Dividendo

Ratio Precio/Utilidad

-6.28

Beneficio por acción (BPA)

-1.43

turnover

Beneficio neto

-100.7M

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.oricpharma.com

Sede

Wilmington, Delaware, USA

Fundado

Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was US$8.96. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of US$ 6.33 to US$ 16.65.

Oric Pharmaceuticals currently has 70,566,950 shares in issue. The market capitalisation of Oric Pharmaceuticals is US$632.28 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.28.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.775	-7.96096558808	9.735	10.21	8.935	210072	9.31685111	CS
4	-1.205	-11.854402361	10.165	10.61	8.105	334787	9.25862285	CS
12	-2.16	-19.4244604317	11.12	12.83	8.105	420837	9.68902617	CS
26	0.62	7.43405275779	8.34	12.83	6.33	492475	9.34257439	CS
52	0.33	3.82387022016	8.63	16.65	6.33	491801	10.19546281	CS
156	-5.69	-38.8395904437	14.65	17.26	2.36	442994	7.47800599	CS
260	-17.04	-65.5384615385	26	40.81	2.36	367410	11.5288755	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
PALIPalisade Bio Inc	US$ 2.95 (110.71%)	1.61M
DBVTDBV Technologies SA	US$ 4.79 (45.59%)	1.37M
CTHRCharles and Colvard Ltd	US$ 2.035 (29.61%)	429.91k
WHLRWheeler Real Estate Investment Trust Inc	US$ 5.50 (23.32%)	76.76k
ONVOOrganovo Holdings Inc	US$ 0.498 (21.61%)	1
PNBKPatriot National Bancorp Inc	US$ 1.08 (-58.78%)	12
AVGRAvinger Inc	US$ 0.40 (-51.22%)	2.54k
SPGCSacks Parente Golf Inc	US$ 0.8796 (-37.17%)	867
BCTXBriaCell Therapeutics Corporation	US$ 0.76 (-30.91%)	23.18k
SFHGSamfine Creation Holdings Group Ltd	US$ 2.33 (-23.61%)	33.08k
AMPGAmplitech Group Inc	US$ 2.03 (5.18%)	1.7M
PALIPalisade Bio Inc	US$ 2.95 (110.71%)	1.61M
DBVTDBV Technologies SA	US$ 4.79 (45.59%)	1.37M
RGTIRigetti Computing Inc	US$ 6.77 (-8.27%)	975.56k
LAESSEALSQ Corporation	US$ 1.12 (-2.61%)	794.31k